Skip to main content

MWG Says It Successfully Opposed Applera Nucleic Acid Amplification Patent

NEW YORK, March 18 - (GenomeWeb News) - MWG Biotech said today that it was successful in opposing a European patent held by Applera over a patent for nucleic acid amplification.

 

The company, based in Ebersberg, Germany, said the European Patent Office revoked Applera's European Patent No. 236 069 B1, entitled "Apparatus and method for performing automated amplification of nucleic acid sequences and assays using heating and cooling steps," after MWG and others had opposed the patent.

 

This decision, the company said, is final. "There are no further judicial remedies," MWG said in a statement.

 

Applera had not issued any public statement on this matter.

 

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.